As of Friday close, Agenus Inc.’s (NASDAQ:AGEN) stock was up $0.08, moving up 5.16 percent to $1.63. The average number of shares traded per day over the past five days has been 7,384,660 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.0400 fall in that time frame. In the last twenty days, the average volume was 4,568,850, while in the previous 50 days, it was 4,514,116.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Since last month, AGEN stock retreated -33.20%. Shares of the company fell to $1.4800 on 05/12/22, the lowest level in the past month. A 52-week high of $6.79 was reached on 01/04/22 after having rallying from a 52-week low of $1.48. Since the beginning of this year, AGEN’s stock price has dropped by -49.38% or -$1.5900, and marked a new high 2 times. However, the stock has declined by -75.99% since its 52-week high.
Agenus Inc. (AGEN) last reported insider trading activity 128 days ago on Jan 06. O’Day Steven J, the Chief Medical Officer of the company, disposed of 38,679 shares for $3.06 on Jan 06. It resulted in a $118,346 divestment by the insider. AGENUS INC added 1,400,000 shares at an average price of $12.00 on Oct 19. The insider now owns 20,881,000 shares following the transaction. On Sep 13, Chairman and CEO ARMEN GARO H sold 82,107 shares at $6.50 apiece. The transaction was valued at $533,696.
The stock’s beta is 1.25. Besides these, the trailing price-to-sales (P/S) ratio of 1.57, the price-to-book (PB) ratio of 12.54.
In the three months ended September 29, Agenus Inc.’s quick ratio stood at 2.10, while its current ratio was 2.10, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 0.37, and the total debt-to-equity ratio was 0.39. On the profitability front, the trailing twelve-month gross margin is 98.80% percent. In the year ended September 29, operating margins totaled 10.80%. Based on annual data, AGEN earned $292.19 million in gross profit and brought in $295.67 million in revenue.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. AGEN’s revenue rose 54.82% to $20.26 million during the quarter, while net income inched up to $25.94 million. While analysts expected Agenus Inc. to report $0.46 quarterly earnings, the actual figure was $0.72 per share, beating the consensus estimate by 56.50%. During the quarter, the company generated -$33.8 million in EBITDA. The liabilities of Agenus Inc. were 413.65 million at the end of its most recent quarter ended September 29, and its total debt was $54.6 million. The value of shareholders’ equity is $270.99 million.
This quick technical analysis looks at Agenus Inc.’s (AGEN) price momentum. With a historical volatility rate of 99.31%, the RSI 9-day stood at 36.67% on 13 May.
With respect to its five-day moving average, the current Agenus Inc. price is down by -2.40% percent or -$0.0400. At present, AGEN shares trade -30.34% below its 20-day simple moving average and -53.82% percent below its 100-day simple moving average. However, the stock is currently trading approximately -44.93% below its SMA50 and -68.59% below its SMA200.
Stochastic coefficient K was 10.97% and Stochastic coefficient D was 9.83%, while ATR was 0.1631. Given the Stochastic reading of 21.43% for the 14-day period, the RSI (14) reading has been calculated as 35.03%. As of today, the MACD Oscillator reading stands at -0.1133, while the 14-day reading stands at -0.2060.
H.C. Wainwright launched its rating on Agenus Inc. (NASDAQ: AGEN) to a Buy in a note to investors on December 16, 2021. Agenus Inc. (AGEN) has been rated Buy by analysts. According to 0 brokerage firms, AGEN is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Agenus Inc. stock as buy, with 4 recommending it as overweight.
With a median target price of $8.00, the current consensus forecast for the stock is $7.00 – $14.00. Based on these forecasts, analysts predict Agenus Inc. (AGEN) will achieve an average price target of $9.67.